Recipharm, a contract development and manufacturing organization, has invested SEK 5 million ($566,000) into a new GLP-compliant bioanalysis laboratory at its development facility in Uppsala, Sweden. The investment will see the opening of a 500-square-meter purpose-built facility in November 2016.

From its new laboratory, Recipharm will increase its capacity, with the capability to process more than 10,000 plasma samples per week. In order to support the increasing demand for bioanalysis services, Recipharm Development in Uppsala plans to recruit several new PhD-level chemists in the coming months and aims to more-than-double its team of 35 in the next couple of years.

Source: Recipharm